Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
Division of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.
Clin Colorectal Cancer. 2017 Sep;16(3):e141-e145. doi: 10.1016/j.clcc.2017.01.006. Epub 2017 Jan 25.
Although several major trials of treatment for stage III colon cancer have been reported, no study has compared oral adjuvant chemotherapy regimens using tegafur-uracil in combination with leucovorin (UFT/LV) and capecitabine (CAPE) alone. This study compared the oncologic outcomes of treatment with these 2 oral regimens.
Records of patients with stage III colon cancer who underwent curative surgery and adjuvant chemotherapy from April 2007 and September 2014 were retrospectively reviewed.
A total of 258 patients with stage III colon cancer received oral adjuvant chemotherapy with UFT/LV (n = 157, 61%) and CAPE (n = 101, 39%). The overall rate of completion of scheduled treatment was 78.6%. Significantly fewer patients on UFT/LV completed the regimen compared with those on CAPE (117, 74.5% vs. 86, 85.1%; P < .01). There were no significant differences in oncologic outcome between UFT/LV and CAPE in terms of 3-year overall survival rates (OS; 95.8% vs. 92.4%, P = .45) and 3-year relapse-free survival rates (RFS; 82.7% vs. 79.3%, P = .8).
The 3-year RFS and OS were similar for both regimens, yielding an excellent outcome. The selection of adjuvant chemotherapeutic regimens must be based on the patient's status as well as considering the incidences of adverse events, medical cost, and administration convenience.
尽管已经报道了几项关于治疗 III 期结肠癌的大型试验，但尚无研究比较过替加氟-尿嘧啶（UFT/LV）联合卡培他滨（CAPE）与单独使用卡培他滨的口服辅助化疗方案。本研究比较了这两种口服方案的肿瘤学结局。
回顾性分析了 2007 年 4 月至 2014 年 9 月接受根治性手术和辅助化疗的 III 期结肠癌患者的病历。
共有 258 例 III 期结肠癌患者接受了 UFT/LV（n=157，61%）和 CAPE（n=101，39%）的口服辅助化疗。计划治疗的总完成率为 78.6%。与 CAPE 组相比，UFT/LV 组完成该方案的患者明显较少（117 例，74.5%比 86 例，85.1%；P<0.01）。在 3 年总生存率（OS；95.8%比 92.4%，P=0.45）和 3 年无复发生存率（RFS；82.7%比 79.3%，P=0.8）方面，UFT/LV 和 CAPE 之间的肿瘤学结果无显著差异。
两种方案的 3 年 RFS 和 OS 相似，均取得了良好的结果。辅助化疗方案的选择必须基于患者的状况，并考虑不良事件的发生率、医疗费用和管理便利性。
